Quickfire Q&A: Francesca Puggioni - European Medical Journal

This site is intended for healthcare professionals

Quickfire Q&A: Francesca Puggioni

Respiratory

Quickfire Q&A delivers in-person insights from congresses, bringing together expert perspectives on the studies and data shaping clinical practice.

In this episode, recorded at the European Respiratory Society (ERS) 2026 Congress, we speak to Francesca Puggioni, IRCCS Humanitas Research Hospital, Milan, Italy, about advances in asthma care, from real-world treatment evidence and long-term disease control to remote monitoring and the management of comorbidities.

Key topics discussed include:

  • Real-world evidence: How data from everyday clinical practice can help assess treatment outcomes, including lung function, oral corticosteroid use, and remission.
  • Long-term disease control: Why asthma care must address current symptoms while preventing exacerbations and preserving future lung function.
  • Remote monitoring: The opportunities offered by digital technologies, and the importance of using registered, reliable medical devices to guide clinical decisions.
  • Comorbidities and severe asthma: Why assessing patients’ overall health is essential to distinguish severe asthma from poor control driven by unmanaged comorbidities.

Disclosure: ALK Abello, AstraZeneca, Chiesi, Sanofi, Stallergenes Greer, Teva – consultancy fees; ALK Abello, Almirall, AstraZeneca, Chiesi, GSK, Menarini, Mundipharma, Sanofi, Stallergenes Greer, Valeas – payment or honoraria for lectures, presentations, speakers’ bureaus, or educational events.

Read the latest issue of EMJ Respiratory for more expert insights and highlights from ERS 2026.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.